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Abstract
Background Risk of hepatocellular carcinoma (HCC) may
be difficult to determine in the clinical setting.
Aim Develop a scoring system to forecast HCC risk among
patients with chronic hepatitis C.
Methods Using data from the Chronic Hepatitis Cohort
Study collected during 2005–2014, we derived HCC risk
scores for males and females using an extended Cox model
with aspartate aminotransferase-to-platelet ratio index
(APRI) as a time-dependent variables and mean Kaplan–
Meier survival functions from patient data at two study
sites, and used data collected at two separate sites for
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external validation. For model calibration, we used the
Greenwood–Nam–D’Agostino goodness-of-fit statistic to
examine differences between predicted and observed risk.
Results Of 12,469 patients (1628 with a history of sustained
viral response [SVR]), 504 developed HCC; median followup was 6 years. Final predictors in the model included age,
alcohol abuse, interferon-based treatment response, and
APRI. Point values, ranging from -3 to 14 (males) and -3 to
12 (females), were established using hazard ratios of the
predictors aligned with 1-, 3-, and 5-year Kaplan–Meier
survival probabilities of HCC. Discriminatory capacity was
high (c-index 0.82 males and 0.84 females) and external
calibration demonstrated no differences between predicted
and observed HCC risk for 1-, 3-, and 5-year forecasts among
males (all p values[0.97) and for 3- and 5-year risk among
females (all p values[0.87).
Conclusion This scoring system, based on age, alcohol
abuse history, treatment response, and APRI, can be used
to forecast up to a 5-year risk of HCC among hepatitis C
patients before and after SVR.
Keywords Hepatocellular carcinoma  Risk  Prediction 
Score  Hepatitis C
Abbreviations
CHeCS Chronic Hepatitis Cohort Study
KM
Kaplan–Meier
APRI
Aspartate aminotransferase-to-platelet ratio
index
HCC
Hepatocellular carcinoma
HCV
Hepatitis C virus
ROC
Receiver operator curve
SVR
Sustained viral response
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Introduction
In the United States, hepatocellular carcinoma (HCC) is
the fifth and ninth leading cause of cancer-related death
among males and females, respectively; most US HCC
cases are attributable to infection with hepatitis C virus
(HCV) [1, 2]. Overall 5-year survival among patients with
HCC is \20% [3]. However, several potentially curative
interventions exist for patients with early stage disease;
these include liver transplantation, liver resection, and
radiofrequency ablation [2].
Identification of HCV-infected patients who should
undergo regular surveillance for HCC and the timing for
implementation of such surveillance are not always clear.
Neither a patient nor provider may be aware of the presence or the point of onset of cirrhosis and, accordingly, the
need for HCC surveillance. Ideally, surveillance should
target patients at high risk of HCC; surveillance of those at
low risk is cost-ineffective and may lead to needless, and
potentially harmful, interventions [1]. Among patients in
the earlier stages of liver disease, risk of HCC could be
periodically assessed and effective treatment could be
instituted before patients transit into a phase of higher
cancer risk. Clinical guidelines from all major world liver
disease societies recommend imaging studies such as
ultrasound every 6 months as the standard of care for
identifying HCV-infected cirrhotic patients with early
stage HCC when the disease may be more amenable to
therapy [4–7].
A number of HCC prediction models have been developed, many of which were limited to HCV-infected
patients with established cirrhosis. Since the development
of many of these models, serum biomarkers such as the
aspartate aminotransferase-to-platelet ratio index (APRI)
and FIB-4 have been shown to correlate well with biopsy
as a means of identifying severe fibrosis and cirrhosis
[8, 9]. As these biomarkers are calculated from routinely
obtained blood tests, they may be applied to virtually all
patients and assessed serially during follow-up.
Older age, low platelet count, and the presence of cirrhosis have been identified as the predominant characteristics that identify HCV-infected patients at risk of HCC,
although several other factors may refine the ascertainment
of risk (e.g., race, family history, esophageal varices,
smoking, and serum albumin, aminotransferase, and alpha
fetoprotein levels) [10–16]. Using these factors, some
classification systems have been developed to stratify
patients into categories of low, intermediate, and high risk,
according to estimates of magnitude and timeframes of risk
[10–12, 14, 15]. In general, these models were developed
using baseline patient characteristics that were fixed and
unchanged over time; most apply strictly to patients with
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untreated HCV infection. It remains challenging, therefore,
to determine the evolving degree of HCC risk over the
course of follow-up, particularly after eradication of
infection. Development of a forecasting tool that accommodates to changing conditions over time, during the
course of a patient’s follow-up, before and after sustained
viral response (SVR), could inform clinician–patient discussions regarding the need to initiate HCC surveillance or,
for those never treated, HCV treatment itself [17].
The objective of our study was to develop a simple point
system to forecast HCC risk among HCV-infected patients
that could be readily applied (and reapplied during followup visits) in the clinic. To this end, we developed risk
estimates using the same methods employed to develop the
Framingham Study risk score functions, which enable
clinicians to forecast cardiovascular disease risk using a
points-based scoring system derived from the values of
several routinely ascertained clinical parameters [18].

Methods
Study Population: Derivation of Development
and Validation Cohorts
We used data collected from patients with chronic hepatitis
C enrolled in the Chronic Hepatitis Cohort Study (CHeCS),
a multicenter observational study whose composition and
criteria for inclusion have been summarized previously
[19]. These data were accessed via electronic health
records and administrative data (supplemented with individual chart review by trained data abstractors) collected
during 2005 through 2014 from persons aged C18 years at
four sites: Geisinger Health System, Danville, PA; Henry
Ford Health System, Detroit, MI; Kaiser PermanenteNorthwest, Portland, OR; and Kaiser Permanente, Honolulu, Hawaii. Chronic HCV infection was confirmed based
on one or more positive HCV RNA tests before antiviral
treatment. Data collected included patient demographics,
medical encounters, receipt of and response to HCV
antiviral therapy, and laboratory and biopsy results.
Patients with human immunodeficiency virus or hepatitis B
virus coinfection were excluded from the analysis. The
parent study protocol was reviewed and approved by an
institutional review board at each participating site.
We set out to develop separate scoring systems for
males and females because (1) of the disparity in HCC
occurrence among males and females, (2) nearly two-thirds
of the CHeCS hepatitis C cohort is male, and (3) the
Framingham scoring system for cardiovascular disease,
upon which our approach was based, uses separate scoring
systems for males and females. Accordingly, we separated
our pooled cohort according to sex and used two of the
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CHeCS study sites (Geisinger Health System and Henry
Ford Health System) for model development and the two
other CHeCS sites (Kaiser Permanente-Northwest and
Hawaii) as the validation cohort.
Selection and Description of Potential HCC Risk
Factors
For inclusion in the prediction model, we selected the
following independent variables known to be or plausibly
associated with HCC: age (as a continuous variable); history of alcohol use disorder (yes/no); history of diabetes
mellitus (yes/no); body mass index (\25, 25–29, C30 kg/
m2); interferon treatment response (yes/no for never treated, IFN failure, and SVR); and APRI score (yes/no for six
time-dependent dummy variables, corresponding to progressively higher score increments). We did not include
other predictors (e.g., HCV genotype and estimated duration of HCV infection) for which we lacked complete data.
With regard to fibrosis biomarkers, we chose to use
APRI rather than FIB-4 as the latter incorporates age in its
calculation. In the event that age and fibrosis score
appeared as discrete predictors in the final model, we
wanted to ensure that our fibrosis measure did not include
patient age.
For each patient, the presence of comorbid diabetes was
based on ICD-9 codes for diabetes without chronic complications: 250.0–250.3, 250.7, 250.00–250.03, 250.07, and
with chronic complications: 250.4–250.6, 250.04–250.06;
alcohol use disorder was based on ICD-9 codes of
291.0–291.9,
303.00–303.03,
303.90–303.93,
305.00–305.03, 980, 291.81, 291.82, or 291.89.
APRI scores were calculated from laboratory data using
the following formula [20]:

APRI ¼

ASTðIU=LÞ=AST upper limit of normal ðIU=LÞ
Platelet count ð109 =LÞ
 100

AST and platelet counts had to have been collected
within 7 days of each other. We calculated each patient’s
average APRI values for each calendar year. To minimize
the possible effect of temporary fluctuations in the component laboratory values that might have been obtained
during acute illness, APRI measurements were excluded if
these laboratory results were collected during hospitalization. We also excluded from the analysis patients who were
missing data that prevented calculation of a single APRI.
Our main outcome was an occurrence of HCC. We
searched for HCC in tumor registry records, according to
CDC’s National Program of Cancer Registries (for Danville and Portland sites) and the National Cancer Institute’s
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Surveillance, Epidemiology, and End Results program (for
Detroit and Honolulu sites) collaborative data collection
standards. Such cancers diagnosed during the follow-up
period were included as HCC cases in the model.
HCC cases and dates of diagnoses (by calendar year)
were ascertained during each patient’s follow-up period;
those whose diagnosis occurred before their initial APRI
score were excluded. Hepatitis C treatment was included in
the analysis if the first treatment start date occurred
between the date of the initial APRI score and the end of
follow-up; persons with a history of SVR achieved before
the first APRI score in the dataset were excluded. Among
cohort patients who received HCV antiviral treatment,
SVR status was based on the availability of one or more
negative HCV RNA tests at least 12 weeks post-treatment
or on clinician determination abstracted from the patient’s
medical chart.
Survival Analysis Dataset
Baseline for each patient with an established diagnosis of
HCV infection commenced on the date of the first calculable APRI after January 1, 2005. Follow-up continued
until the date of HCC diagnosis; for patients in whom HCC
did not occur, data were right-censored at the date of death,
or the date of the earliest occurring of liver transplant
(based on ICD-9 diagnosis or procedure codes of 996.82,
50.5, 50.51, 50.59, 47,135, or 47,136), 2 years following
the last APRI measurement, or on December 31, 2014, if
none of the aforementioned events occurred.
Prognostic Model Selection and Assessment
of Discrimination
We selected our prognostic model using best subsets
regression to identify predictors of importance and calculated the Harrell’s c-index [21–23], a measure of the
model’s discriminatory accuracy (i.e., the model’s capacity
to distinguish subjects at high vs. low risk of HCC) that is
analogous to the area under the receiver operator characteristic (ROC) curve [23, 24]. A c-index of 0.5 indicates no
discriminatory accuracy, and an index of 1.0 represents
perfect discrimination. To examine whether the c-index
required adjustment, we performed bootstrapping with
replacement using 80% of original dataset on 100 subdatasets of the same sample size generated from the original dataset.
We estimated the optimism of our prognostic model
selection and validation, as suggested by Harrell [25], with
the
macros
‘‘Harrell_Optimism_Cox’’ [21] and
‘‘SURVCSTD’’ [22]. Initially including all predictors (i.e.,
age, alcohol use disorder history, diabetes history, history
of HCV antiviral treatment, body mass index, and APRI) in
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Table 1 Characteristics of hepatitis C virus-infected patients with and without hepatocellular carcinoma, Chronic Hepatitis Cohort Study,
2005–2014
Variables

Male
Total
N = 7372

Female
Development
(n = 4741)

Validation
(n = 2631)

p value

Total
N = 5097

Development
(n = 3413)

Validation
(n = 1684)

p value

Duration of follow-up
N

7372

4741

2631

5097

3413

1684

Median

6.3

5.9

6.9

6.5

6.1

7.3

Range

0.5–10.0

0.5–10.0

0.5–10.0

Mean (SE)

6.2 (0.03)

6.0 (0.04)

6.7 (0.06)

Total

28,346.7

17,506.3

21,016.2

11,615.2

Post-SVR

2790.6

2454.0

2451.0

1710.2

\0.001

0.5–10.0

0.5–10.0

0.5–10.0

6.4 (0.04)

6.2 (0.05)

6.9 (0.07)

\0.001

Person-year follow-up

Number of clinic visitsa per person-year during follow-up
N

7146

4546

2600

4968

3302

1666

Median

6.2

5.3

7.3

6.8

5.9

8.4

Range

0.1–380.1

0.1–120.9

0.3–380.1

0.1–368.9

0.1–123.9

0.2–368.8

Mean (SE)

10.4 (0.2)

9.5 (0.2)

12.1 (0.4)

11.2 (0.3)

9.5 (0.2)

14.5 (0.7)

Age (years) at baseline
N
7372

\0.001

4741

2631

5097

3413

1684

Median

53

53

53

51

51

51

Range

14–95

15–95

14–91

16–90

16–90

17–89

Mean (SE)

52 (0.1)

51 (0.2)

52 (0.2)

0.05

49 (0.2)

48 (0.2)

51 (0.2)

No

6985 (94.8)

4492 (94.7)

2493 (94.8)

1.000

4980 (97.7)

3334 (97.7)

1646 (97.7)

Yes

387 (5.2)

249 (5.3)

138 (5.2)

117 (2.3)

79 (2.3)

38 (2.3)

\0.001

\0.001

HCC

HCC post-SVR

33 (0.4)

15 (0.3)

18 (0.7)

10 (0.2)

6 (0.2)

4 (0.2)

HCC post-IFN
failure

127 (1.7)

91 (1.9)

36 (1.4)

0.04

43 (0.8)

24 (0.7)

19 (1.1)

HCC never
treated

227 (3.1)

143 (3.0)

84 (3.2)

64 (1.3)

49 (1.4)

15 (0.9)

1.000
0.15

SVR status
\0.001

SVR

914 (12.4)

529 (11.2)

385 (14.6)

714 (14.0)

445 (13.0)

269 (16.0)

IFN failure

1071 (14.5)

748 (15.8)

323 (12.3)

665 (13.0)

493 (14.4)

172 (10.2)

Never treated

5387 (73.1)

3464 (73.1)

1923 (73.1)

3718 (72.9)

2475 (72.5)

1243 (73.8)

White

4669 (63.3)

2832 (59.7)

1837 (69.8)

3308 (64.9)

2130 (62.4)

1178 (70.0)

Black

1639 (22.2)

1523 (32.1)

116 (4.4)

1114 (21.9)

1032 (30.2)

82 (4.9)

\0.001

Race
\0.001

Asian

200 (2.7)

56 (1.2)

144 (5.5)

188 (3.7)

52 (1.5)

136 (8.1)

Other/
unknown

864 (11.7)

330 (7.0)

534 (20.3)

487 (9.6)

199 (5.8)

288 (17.1)

219 (8.6)

744 (14.8)

538 (15.8)

206 (12.7)

1023 (20.3)

1023 (30.0)

\0.001

Insurance (93 missing)
\0.001

Medicaid

730 (10.0)

511 (10.8)

Medicare only

1517 (20.8)

1517 (32.0)

Medicare plus

854 (11.7)

263 (5.5)

591 (23.3)

500 (9.9)

157 (4.6)

343 (21.2)

Private

3802 (52.2)

2074 (43.7)

1728 (68.1)

2342 (46.5)

1272 (37.3)

1070 (66.1)

None

376 (5.2)

376 (7.9)

423 (8.4)

423 (12.4)
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Table 1 continued
Variables

Male
Total
N = 7372

Female
Development
(n = 4741)

Validation
(n = 2631)

p value

Total
N = 5097

Development
(n = 3413)

Validation
(n = 1684)

p value

\0.001

\0.001

BMI (kg/m2)
\25

2584 (35.1)

1924 (40.6)

660 (25.1)

2110 (41.4)

1502 (44.0)

608 (36.1)

25–30

2547 (34.5)

1447 (30.5)

1100 (41.8)

1365 (26.8)

875 (25.6)

490 (29.1)

[30

2241 (30.4)

1370 (28.9)

871 (33.1)

1622 (31.8)

1036 (30.4)

586 (34.8)

No

6712 (91.0)

4316 (91.0)

2396 (91.1)

Yes

660 (9.0)

425 (9.0)

235 (8.9)

No

5218 (70.8)

3459 (73.0)

1759 (66.9)

Yes

2154 (29.2)

1282 (27.0)

872 (33.1)

Diabetesb
1.000

4719 (92.6)

3146 (92.2)

1573 (93.4)

378 (7.4)

267 (7.8)

111 (6.6)

4210 (82.6)

2901 (85.0)

1309 (77.7)

887 (17.4)

512 (15.0)

375 (22.3)

0.12

Alcohol abuseb
\0.001

\0.001

Baseline APRI (all patients)
\1.0

4664 (63.3)

3013 (63.6)

1651 (62.8)

3664 (71.9)

2398 (70.3)

1266 (75.2)

1.0–2.0

1353 (18.4)

829 (17.5)

524 (19.9)

755 (14.8)

520 (15.2)

235 (14.0)

[2.0

0.02

1355 (18.4)

899 (19.0)

456 (17.3)

678 (13.3)

495 (14.5)

183 (10.9)

APRI at SVR
N

898

513

385

702

434

268

\1.0

748 (83.3)

427 (83.2)

321 (83.4)

597 (85.0)

375 (86.4)

222 (82.8)

1.0–2.0

111 (12.4)

62 (12.1)

49 (12.7)

67 (9.5)

34 (7.8)

33 (12.3)

[2.0

39 (4.3)

24 (4.7)

15 (3.9)

38 (5.4)

25 (5.8)

13 (4.9)

2631

5097

3413

1684
1240 (73.6)

0.825

\0.001

0.1364

Last APRI (all patients)
N

7372

4741

\1.0

4777 (64.8)

3072 (64.8)

1705 (64.8)

3651 (71.6)

2411 (70.6)

1.0–2.0

1280 (17.4)

839 (17.7)

441 (16.8)

760 (14.9)

525 (15.4)

235 (14.0)

[2.0

1315 (17.8)

830 (17.5)

485 (18.4)

686 (13.5)

477 (14.0)

209 (12.4)

898

513

385

702

434

268

Median

5.77

5.00

6.60

6.08

5.63

6.76

Range

0.79–10.00

0.79–10.00

0.80–10.00

0.76–10.00

0.81–10.00

0.76–10.00

Mean (SE)

5.84 (0.10)

5.44 (0.13)

6.37 (0.15)

5.93 (0.11)

5.65 (0.14)

6.38 (0.18)

4087

1713

4006

2928

1078

0.4344

0.0820

Follow-up post-SVR (years)
N

Baseline HCV RNA level
N
5800
\500,000

1924 (33.2)

1426 (34.9)

498 (29.1)

C500,000

3876 (66.8)

2661 (65.1)

1215 (70.9)

N

7273

4662

Normal

1061 (14.6)

762 (16.3)

1–29 ULNb

2100 (28.9)

[29 ULN

4112 (56.5)

\0.001

1587 (39.6)

1293 (44.2)

294 (27.3)

2419 (60.4)

1635 (55.8)

784 (72.7)

2611

5036

3368

1668

299 (11.5)

448 (8.9)

313 (9.3)

135 (8.1)

1438 (30.8)

662 (25.4)

1231 (24.4)

832 (24.7)

399 (23.9)

2462 (52.8)

1650 (63.2)

3357 (66.7)

2223 (66.0)

1134 (68.0)

7266

4657

2609

5040

3369

1671

5223 (71.9)

3256 (69.9)

1967 (75.4)

4098 (81.3)

2688 (79.8)

1410 (84.4)

2043 (28.1)

1401 (30.1)

642 (24.6)

942 (18.7)

681 (20.2)

261 (15.6)

\0.001

0.003

\0.001

Baseline ALTc

\0.001

0.2539

Baseline platelet countd
N
Normal
\Normal

\0.001

\0.001

Liver biopsy
No
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Table 1 continued
Variables

Male
Total
N = 7372

Female
Development
(n = 4741)

Validation
(n = 2631)

p value

Total
N = 5097

Development
(n = 3413)

Validation
(n = 1684)

130 (29.1)

p value

Yes (METAVIR stage)
F0–F1

465 (33.4)

343 (47.7)

122 (18.2)

424 (44.4)

294 (57.8)

F2–F3

615 (44.2)

211 (29.3)

404 (60.1)

387 (40.5)

130 (25.5)

257 (57.5)

F4

311 (22.4)

165 (22.9)

146 (21.7)

145 (15.2)

85 (16.7)

60 (13.4)

\0.001

\0.001

ALT alanine aminotransferase, APRI aspartate aminotransferase-to-platelet ratio index, BMI body mass index, HCC hepatocellular carcinoma,
SVR sustained virologic response at 12 weeks, ULN upper limit of normal
a

Clinic visits include ambulatory visit or emergency department visit (excludes urgent care visit)

b

Diabetes mellitus and alcohol misuse/dependence according to ICD-9 code
ALT upper limit of normal: 30 IU/mL for men, 19 IU/mL for women

c

d

Platelet count lower limit of normal cutoff: 150,000 cells/mL

the original dataset (N), we generated M = 100 datasets of
the same sample size n from the development cohort
dataset size N, where n \ N, using bootstrap samples with
replacement. For each one of the new datasets
m = 1,…,M, the same algorithmic approach as above was
used to calculate the bootstrap Harrell’s c-index (c(m)
boot). For
each one of the 100 new models, we calculated its Harrell’s
c-index, as applied to the original dataset (N) (c(m)
orig). For all
bootstrap samples, the optimism in the fit was O(m) =
(m)
c(m)
boot - corig. The average of these values was the optimism
of the original model:
PM
ðmÞ
 ¼ m¼1 O
O
M
The optimism-corrected performance of the final model
 From that model, the apparent Harwas cadj ¼ capp  O.
rell’s c-index was calculated.
Development of Scoring System for HCC Risk
We developed our HCC risk estimates with the same
methods used to develop the Framingham Study risk score
functions, performing a series of steps as suggested by
Sullivan [18]. This process first involved computing the
mean Kaplan–Meier (KM) survival function over 1, 3, and
5 years of follow-up and then computing an extended Cox
model (i.e., with APRI as a time-dependent variable) with
regression coefficients for the predictors selected and validated from the previous sections. An extended Cox model
was preferred over a standard model because we hypothesized that the APRI trajectory might differ before (i.e.,
progressively higher scores) and after (i.e., progressively
lower scores) SVR. In order to derive time-dependent
regression coefficients for APRI, for each patient we calculated mean annual (calendar year) APRI values from
2005 to 2014. Patients did not necessarily undergo the
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same frequency and timing of laboratory assessments (to
calculate APRI score), although nearly all patients had at
least one APRI score available per year of follow-up. Mean
annual values derived from a single APRI score were
accepted; those without at least one APRI for two consecutive years were right-censored at the date of the last
available APRI score. We then built a matrix for all participants vis-à-vis their specific yearly mean APRI scores
in a dataset. For those who had HCC, we marked a
timestamp in the year of event (HCC diagnosis) and rightcensored all yearly mean APRI after that year. Meanwhile,
for those who did not have HCC, we used all mean annual
APRI scores and right-censored at death, departure from
the CHeCS, or the end of the study period follow-up in
2014 (whichever came first). Finally, we applied this
dataset to survival analysis using SAS PROC PHREG. The
mean annual APRI scores were applied as Heaviside
functions in the model, i.e., the value of yearly APRI was
assigned to the model one at a time for each specific year.
The regression coefficients for each predictor variable
were then weighted, according to their mean or proportion
distribution in the model development cohort. Each predictor variable was divided into categories; for age, we
used 5-year segments and assigned the lowest age in each
segment as the comparative age against the main age referent (e.g., age 20 years was used as the main referent for
males and females), for the treatment variable (IFN-based
treatment response, as the data were collected before
release of the second-generation direct acting antiviral
drugs) we used ‘‘never treated’’ as the referent (vs. IFN
failure and SVR), and for the remaining variables (all yes/
no dummy variables) we used ‘‘no’’ as the referent. We
then calculated the degree of increased risk of HCC relative
to the referent for each category and assigned point values,
accordingly, for all category segments. For each variable,
we determined its minimum and maximum point value
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CHeCS HCV Cohort (2005-2014)
N=12,469

Males
N=7,372

Development1
cohort
N=4,741

Females
N=5,097

Development1
cohort
N=3,413

Validaon2
cohort
N=2,631

Validaon2
cohort
N=1,684

HCC cases
N=504

HCC cases1
N=249

HCC cases2
N=138

HCC cases1
N=79

HCC cases2
N=38

Post-SVR (15)
Post-IFN failure (91)
Never treated (143)

Post-SVR (18)
Post-IFN failure (36)
Never treated (84)

Post-SVR (6)
Post-IFN failure (24)
Never treated (49)

Post-SVR (4)
Post-IFN failure (19)
Never treated (15)

1

Comprised of HCV paents from Henry Ford Health System (Detroit MI) and Geisinger Health System (Danville PA)
of HCV paents from Kaiser Permanente Northwest (Portland OR) and Kaiser Permanente Hawaii (Honolulu HI)

2Comprised

Fig. 1 Derivation of the model development and validation cohorts, Chronic Hepatitis Cohort Study

contributions, the sums of which provided a range of total
point values for all predictor variables in the model. For
each possible total point value, we calculated 1-, 3-, and
5-year risk estimates of HCC and represented these in
condensed tables for clinical use, separately for males and
females (see Supporting Information for detailed methods).
Model Calibration
We applied the Greenwood–Nam–D’Agostino goodnessof-fit statistic as a test of calibration. The Greenwood–
Nam–D’Agostino statistic is a modification of the Nam–
D’Agostino goodness-of-fit test developed for longitudinal
survival models and serves a purpose similar to the Hosmer–Lemeshow goodness-of-fit test used for logistic
regression models [26, 27]. We calibrated our prediction
score model according to the 1, 3-, and 5-year risk estimates of HCC by calculating the prediction score total
point value for each patient and obtaining the corresponding predicted probability of HCC. We then categorized total points into groups (four groups for males and

three for females, based on the distribution of point scores)
and calculated the mean predicted probability of HCC for
each group. Lastly, we calculated observed HCC risk with
the KM method for each group, determining the variance
of each and the corresponding Chi-square and p values for
the 1-, 3-, and 5-year risk estimates (see Supporting
Information for detailed methods).
All statistical analyses were conducted using SAS 9.3
(Cary, NC).

Results
Characteristics of the Development Cohort
and Validation Cohorts
Table 1 shows characteristics of HCV-infected patients
with and without HCC during 2005–2014, according to sex
and representation in the development and validation
cohorts; the derivation of these cohorts from the larger
CHeCS hepatitis C cohort is shown in Fig. 1. There were
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Table 2 An example of the best subset models selected in first 10 bootstrap samples from total 100 bootstraps used to determine the overall
model c-index (example using male cohort)
1
Sample

2
Variablesa in best
subset model

3
Number of
variables in best
subset model

4
Harrell’s c-index from best
subset model fit to bootstrap
dataset (80% sampling)

5
Harrell’s c-index from best subset model fit
to bootstrap dataset, applied to original
dataset (100% sampling)

6
Difference
(i.e.,
optimism)

1

Age1 AlcoAbuse
Svr2 Ap6 Ap5
Ap3 Ap2

7

0.8099

0.8155

-0.005559

2

Age1 AlcoAbuse
Svr2 Ap6 Ap5
Ap3 Ap2

7

0.8145

0.8232

-0.008666

3

Age1 AlcoAbuse
Svr2 Ap6 Ap5
Ap4 Ap3 Ap2

8

0.8158

0.8366

-0.020778

4

Age1 AlcoAbuse
Svr2 Ap6 Ap5
Ap3 Ap2

7

0.8102

0.8215

-0.011238

5

Age1 AlcoAbuse
Svr2 Ap6 Ap5
Ap2

6

0.7864

0.8126

-0.026223

6

Age1 Bmi3
AlcoAbuse Svr2
Ap6 Ap5 Ap3
Ap2

8

0.8044

0.8162

-0.011829

7

Age1 AlcoAbuse
Svr2 Ap6 Ap3
Ap2

6

0.8087

0.8172

-0.008450

8

Age1 AlcoAbuse
Svr2 Ap6 Ap5
Ap3 Ap2

7

0.7871

0.8275

-0.040415

9

Age1 AlcoAbuse
Svr2 Ap6 Ap3
Ap2

6

0.7823

0.8160

-0.033685

10

Age1 AlcoAbuse
Ap6 Ap5 Ap4
Ap3 Ap2

7

0.7959

0.8332

-0.037272

Overall c-index = Average of Column 4 - Average of Column 6 = 0.7956 - (-0.0210) = 0.8166
For inclusion in the prediction model, we selected the following independent variables known to be or plausibly associated with HCC: age (as a
continuous variable); history of alcohol use disorder (yes/no); history of diabetes mellitus (yes/no); body mass index (\25, 25–29, C30 kg/m2—
corresponding to Bmi1–3 above); interferon treatment response (yes/no for never treated, IFN failure, and SVR, corresponding to Svr1-3 above); and
APRI score (yes/no for six time-dependent dummy variables, corresponding to progressively higher score increments, corresponding to Ap1-6 above)

a

12,469 patients in the pooled cohort: 7372 were male and
5097 were female, which included 914 (12.4%) men and
714 (14.0%) women who achieved SVR during follow-up.
During follow-up, 504 patients developed HCC, of whom
387 were male (5.2% of all males) and 117 were female
(2.3% of all females). Among male HCC cases, 227
occurred among patients never treated, 127 occurred after
IFN treatment failure, and 33 occurred after SVR; among
female cases, 64 occurred among patients never treated, 43
occurred following IFN failure, and 10 occurred after SVR.
Both male and female cohorts were comprised predominantly of persons who were white, had private healthcare
insurance, and had BMI C25 kg/m2; 9.0% of males and
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7.4% of females had diabetes, and 29.2% of males and
17.4% of females had a history of an alcohol use disorder.
The median age at initiation of follow-up (i.e., first APRI
score) was 53 years for males and 51 years for females;
median duration of follow-up was 6.3 years for males and
6.5 years for females. At the initiation of follow-up, 63.3%
of males and 71.9% of females had an APRI \1.0 and
18.4% of males and 13.3% of females had an APRI [2.0.
The median age at HCC diagnosis was 58 (range 35–65)
years for males and 60 (range 46–75) years for females.
Among patients who had achieved SVR, the median APRI
at SVR was 0.43 for men and 0.36 for women; the median
duration of post-SVR follow-up was 5.0 years for men and
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Table 3 Extended Cox hazards regression coefficients from the final model, by sex
Risk factor

Male

Female

Regression coefficient

Hazard ratio

p value

Regression coefficient

Hazard ratio

p value

Age

0.05

1.05

\0.001

0.06

1.07

\0.001

Alcohol abuse

0.62

1.87

\0.001

0.60

1.82

0.03

Never treated

0.17

1.18

0.54

-0.01

0.99

0.99

IFN failure

1.01

2.74

\0.001

0.48

1.62

0.30

SVR

0

1

–

0

1

–

APRI 0–1.0

0

1

–

0

1

–

APRI 1.0–2.0
APRI 2.0–3.0

1.15
1.20

3.15
3.31

\0.001
\0.001

1.69
2.12

5.39
8.35

\0.001
\0.001

APRI 3.0–4.0

1.23

3.43

\0.001

1.99

7.28

\0.001

APRI 4.0–5.0

1.56

4.77

\0.001

2.30

9.98

\0.001

APRI [5.0

2.04

7.70

\0.001

2.60

13.44

\0.001

6.1 years for females. Table 1 further demonstrates that
there were significant differences between the development
and validation cohorts among males and females for nearly
all variables (i.e., race, insurance status, BMI, alcohol
abuse history, baseline APRI, age at first APRI, IFN
response, duration of total follow-up, and frequency and
duration of post-SVR follow-up among patients successfully treated).
Model Selection and Validation (Discrimination)
In the final model, we included age, history of alcohol use
disorder, IFN treatment response, and APRI score for
males and females (additional details are provided with
Supporting Information, Supplementary Table 1a [males]
and 1b [females], and Supplementary Table 2). The cindex, which corresponds to the area under the ROC curve,
for males was 0.82 (the derivation of which is shown in
Table 2) and for females was 0.84, consistent with good
discriminatory capacity.
Development of HCC Risk Scoring System, by Sex
We computed an extended Cox model with regression
coefficients for age, alcohol use disorder, IFN treatment
response, and APRI (as a time-dependent variable),
according to sex, as well as the mean KM survival function
over 1, 3, and 5 years of follow-up. Extended Cox hazard
regression coefficients for the variables in the final model
are shown in Table 3. The minimum and maximum point
value contributions for each variable and the range of total
point values are shown in 4a (males) and 4b (females). For

each possible total point value, we calculated 1-, 3-, and
5-year risk estimates for HCC and represented these in
condensed tables for clinical use, one for males and another
for females (Table 5a, b). Prediction scores of 6 for males
corresponded to a 1.5% and scores of 8 for females corresponded to a 1.8% annual risk of HCC; the commensurate 3- and 5-year risk estimates were, respectively, 2.3 and
2.9% for males, and 2.7 and 3.4% for females. Tables 4
and 5 should be applied for direct clinical use (additional
details are provided with Supporting Information, Supplementary Tables 3a, 3b, 4a, and 4b).
Model Calibration
The results of external calibration, demonstrating differences between the score-predicted and KM-observed HCC
risk, for 1-, 3-, and 5-year forecasts, are shown in Fig. 2a
(males) and 2b (females). There were no significant differences between predicted and observed HCC risk for 1-,
3-, and 5-year forecasts among males (p = 0.977, 0.990,
and 0.996, respectively) and for 3- and 5-year risk among
females (p = 0.873 and 0.992, respectively). The Greenwood–Nam–D’Agostino goodness-of-fit statistic could not
be applied to calibrate 1-year HCC risk among females
because there were an insufficient number of observed
cases to provide a comparison prediction score group.
In general, the predicted risk derived from scores
exceeded the KM-observed risk, although the absolute
difference between observed and predicted values
decreased with progressively longer forecast intervals and
with higher prediction scores [Figs. 2a, b; additional details
available in Supporting Information, Supplementary
Table 5a (males) and 5b (females)].
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Table 4 Model-derived point values for the clinical scoring system
for 1-, 3-, and 5-year estimates of hepatocellular carcinoma risk
among patients with chronic hepatitis C, according to risk factors and
categories, for males (a) and females (b)
Score components

Table 4 continued
Score components
Risk factor

Points

0–1.0

0

[1.0–2.0

5

a. Male

[2.0–4.0

6

Age (years)

[4.0–5.0
[5.0

7
8

Risk factor

Alcohol use disorder
Treatment history

APRI

APRI

Categories

Categories

Points

20–24

-3

25–29

-2

30–34

-1

35–39

0

40–44

1

45–49

2

50–54

3

55–59

4

60–64
65–69

5
6

70–74

7

75–79

8

80–84

9

[85

10

No

0

Yes

2

Never treated

1

IFN failure

4

SVR

0

0–1.0

0

[1.0–2.0

4

[2.0–4.0

5

[4.0–5.0

6

[5.0

8

20–24

-3

25–29

-2

30–34

-1

35–39

0

40–44

1

45–49

2

50–54

3

55–59

4

60–64

5

65–69

6

70–74

7

75–79

8

80–84

9

b. Female
Age

C85

10

Alcohol use disorder

No
Yes

0
2

Treatment history

Never treated

0

IFN failure

2

SVR

0
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Discussion
Using data collected from patients with chronic hepatitis C
during 2005–2014 at two large US healthcare organizations
(Henry Ford Health System, Detroit, MI and Geisinger
Health System, Danville, PA), we developed a model and
HCC prediction scoring system for males and females,
incorporating age, treatment response, alcohol use disorder
history, and APRI score. We externally validated this
model using 2005–2014 data from patients with hepatitis C
at two other study sites (Kaiser Permanente, Portland, OR,
and Kaiser Permanente, Honolulu, HI), whose demographic and clinical characteristics differed significantly
from those of patients from the model development sites.
Validation of the model consisted of assessments of discrimination and calibration. Its capacity for discrimination
between HCV-infected patients at high versus low risk of
HCC was high, with a c-index [0.8 for both sexes. The
Greenwood–Nam–D’Agostino goodness-of-fit statistic for
calibration demonstrated overall good predictive capacity,
though the model was superior for predicting 3- and 5-year
HCC risk than for predicting 1-year risk. Its performance
was also better for males than for females (largely because
of higher HCC case numbers for males) and at higher
rather than lower total point scores. As we used pre- and
post-SVR longitudinal clinical data for model development
[28] and incorporated APRI score as a time-dependent
variable in an extended Cox model (rather than a baseline
score in a standard Cox model), this scoring system may be
readily applied and reapplied in any clinical setting during
the course of follow-up as a patient’s age and APRI score
change, before and after achievement of SVR. Thus, the
score can be individualized to patients at any point during
follow-up and can provide an immediate forecast of HCC
risk according to evolving risk determinants over time.
For example, a 52-year-old, treatment-naı̈ve male with
no alcohol abuse history and an APRI score of 0.9 would
have, using Table 4, a risk score of 4, which corresponds in
Table 5 to 1-, 3-, and 5-year risk of HCC of 0.9, 1.4, and
1.7% in Table 5. If the same patient were seen 6 years
later, had remained untreated, and had an APRI score of
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Table 5 Point totals with corresponding 1-, 3-, and 5-year estimates
of hepatocellular carcinoma risk among patients with chronic hepatitis C, for males (a) and females (b)
Total points

HCC risk (%)
1 year

3 years

5 years

-3

0.1

0.2

0.3

-2

0.2

0.3

0.4

a. Male

-1

0.2

0.4

0.5

0

0.3

0.5

0.6

1

0.4

0.6

0.8

2

0.5

0.8

1.0

3

0.7

1.0

1.3

4

0.9

1.4

1.7

5

1.2

1.8

2.2

6

1.5

2.3

2.9

7

2.0

3.0

3.8

8

C2.5a

3.8

4.9

9
10

5.0
6.4

6.3
8.1

11

C8.3a

10.4

12

13.3

13

17.0

14

C21.5

b. Female
-3

0.1

0.1

0.1

-2

0.1

0.1

0.1

-1

0.1

0.1

0.2

0

0.1

0.2

0.3

1

0.2

0.3

0.4

2

0.3

0.4

0.5

3

0.4

0.5

0.7

4

0.5

0.7

1.0

5
6

0.7
1.0

1.0
1.4

1.3
1.8

7

1.3

1.9

2.5

8

C1.8a

2.7

3.4

9

C3.6a

4.7

10

6.4

11

8.7

12

C11.8

a

Since there were so few individuals in the upper ranges of the distribution, we cut off the risk table to avoid overstating the precision in
the risk estimates

1.8, his total score from Table 4 at this point would be 9,
corresponding in Table 5 to 1-, 3-, and 5-year HCC risk of
[2.5, 5.0, and 6.3%, respectively.
The importance of patient age with regard to HCC risk
is evident in our scoring system. In our system, every
5-year increment in advancing age translated to an

additional point added to the point total (e.g., a male aged
55–59 years would receive 4 points and one aged
60–64 years would receive 5 points). Patient age has been
identified as a major risk factor for HCC among HCVinfected persons, and investigators have found that even
when stratified by stage of fibrosis (except among those
with cirrhosis), the incidence of HCC was higher among
older versus younger patients, and that fibrosis progression
accelerated after age 50 years regardless of duration of
infection [29–35].
Interferon treatment failure was an important characteristic of the model, a history of which contributed four
points for men and two for women to their point totals.
That interferon treatment failure was associated with a
more rapid progression of liver disease (compared to
untreated persons) was consistent with what we reported,
using separate methodology, in another publication [36],
and is consistent with the findings of Baran et al. [37].
There are a few issues with the application of the
scoring system that could be encountered in clinical practice. As we used mean calendar year APRI scores for
model development, if serial values are available, we
suggest that clinicians use a patient’s mean APRI score
over a period rather than rely on a single value. Characterization of alcohol use disorder for model development
was based on ICD-9 codes, which been shown to underestimate the prevalence of alcohol abuse and dependence
when compared with the prevalence ascertained through
direct patient questioning. For example, our group found
ICD-9 codes to be insensitive but highly specific (i.e.,
[90%) for detecting alcohol use disorders [38]. With
respect to use of the scoring system in a clinical setting,
providers should have the discretion of adding points for
alcohol use disorder based on knowledge of or a high index
of clinical suspicion of such a disorder, independent of
whether a patient had an ICD-9 code-based diagnosis in his
or her medical record.
There are limitations to our model and scoring system.
Application of the system should be limited to HCV
monoinfected persons, as persons with known HBV or HIV
infection were excluded from the development cohort. As
mentioned, data used for development and validation of the
model were largely collected during the IFN treatment era,
so it is possible the system may not entirely reflect conditions and outcomes related to widespread use of DAAs.
Since we had a relatively low number of genotype 3
patients among patients with known genotype, and because
genotype data were missing for a large fraction of patients
who were never treated, we were unable to assess whether
genotype might serve as a predictor variable (e.g., whether
patients with genotype 3 infection might accrue more
points compared to non-genotype 3 patients). Although we
did not include nonalcoholic fatty liver disease specifically

123

3232

Dig Dis Sci (2017) 62:3221–3234

(a) Male

(b) Female

External validation sample, 1-year HCC risk for men

External validation sample, 1-year HCC risk for women
0.01

Observed

0.025

Observed

Predicted

1-Year HCC risk

1-Year HCC risk

0.03

p-value=0.977

0.02
0.015
0.01
0.005

0.008
0.006
0.004
0.002
0

0
1

2

1

3

Groups

Groups

External validation sample, 3-year HCC risk for women

External validation sample, 3-year HCC risk for men

0.04
Observed

0.08

Predicted

3-Year HCC risk

3-Year HCC risk

0.1
p-value=0.990

0.06
0.04
0.02

Observed
0.03

1

0.02
0.01

2

3

1

4

Groups

Observed

Predicted

5-Year HCC risk

5-Year HCC risk

External validation sample, 5-year HCC risk for women
0.12

0.2

2

Groups

External validation sample, 5-year HCC risk for men

p-value=0.996

0.15
0.1
0.05
0

Predicted

p-value=0.873

0

0

0.25

Predicted

p-value=N/A

0.1

Observed

Predicted
p-value=0.992

0.08
0.06
0.04
0.02
0

1

2

3

4

Groups

1

2

3

Groups

Fig. 2 a, b Calibration bar grafts comparing predicted estimate of hepatocellular carcinoma (HCC) risk (derived from the development cohort)
versus observed HCC cases in the external validation cohort, for males (a) and females (b)

as a predictor variable, we included BMI and DM as candidate variables in the prediction model, neither of which
was determined to belong in the final model. Nonetheless,
we believe this simple scoring system for estimating HCC
risk can serve as a useful tool to guide decision-making for
patients and clinicians. Validation with other pre- and postSVR cohorts, particularly as more data collected from the
DAA era are available, may help further refine and
improve its predictive capacity. Given the expanding
population of persons in whom HCV infection has been
eradicated by the use of DAAs, it will be necessary to
determine in the future whether and to what degree these
risk estimates should be modified.
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